Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555079 | 1.00 | USP2 (0.51) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL554849 | 1.00 | USP2 (0.51) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| Hydrochloric Acid SCHEMBL31601582 | 0.99 | USP2 (0.50) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| Acetic Acid SCHEMBL31055697 | 0.96 | USP2 (0.48) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL8004062 | 0.92 | MAPT (0.48) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL13779825 | 0.92 | MAPT (0.48) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL15107826 | 0.92 | MAPT (0.48) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL19448345 | 0.89 | USP2 (0.49) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL18689612 | 0.89 | USP2 (0.49) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL19439155 | 0.89 | USP2 (0.49) | USP2SMN1; SMN2RECQLNR1H2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-12428395-B2 | Heterocyclic compounds as kinase inhibitor and uses thereof | SPEROGENIX THERAPEUTICS LIMITED (CN) | 2025-09-30 | — | — | US | disclosed |
| EP-4007757-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | SPEROGENIX THERAPEUTICS LTD (HK) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025124586-A1 | DEGRADABLE CATIONIC LIPID CONTAINING DISULFIDE BOND AND USE THEREOF | 厦门赛诺邦格生物科技股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-4558137-A2 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002026723-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| US-5763436-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5595999-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5583133-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5532232-A | INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD | HOFFMANN-LA ROCHE INC. (US) | 1996-07-02 | — | — | US | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0468231-B1 | Guanidins | HOFFMANN LA ROCHE (CH) | 1994-09-21 | — | — | EP | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0468231-A2 | Guanidins | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDK6, CDKL1, CDK3 | USP2 2191/4885SMN1; SMN2 4257/4885RECQL 1698/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885 |
| US-12428395-B2 | Heterocyclic compounds as kinase inhibitor and uses thereof | CHEK1, CHEK2, CHKA | USP2 1464/4885SMN1; SMN2 3709/4885RECQL 729/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | USP2 1360/4885SMN1; SMN2 318/4885RECQL 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.